Keytruda, Pfizer combo gets FDA ok for advanced kidney cancer

The U.S. FDA approved Merck ' s blockbuster Keytruda in combination with Pfizer ' s Inlyta as a first-line treatment for advanced renal call carcinoma — kidney cancer that has spread, despite earlier treatments.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news